Halda has built a suite of tools and know-how to discover and develop RIPTAC™ therapeutics from conception to design to optimization for the clinic. Our platform enables the modular design of RIPTAC therapeutics as a novel heterobifunctional drug modality for precision cancer treatment.
With hundreds of cancer selective intracellular protein markers and hundreds of proteins with essential function to choose from, we have developed an algorithm to help select complementary pairs to begin the RIPTAC therapeutic design.
There are three critical components to a RIPTAC therapeutic:
Halda takes advantage of today’s advanced tools for structure-based drug design and internal expertise of bifunctional molecule design and synthesis to ensure proper alignment of proteins to drive the formation of neo protein-protein interactions and selective cell death.
Once designed, we iteratively test the kinetics of ternary complexes containing the RIPTAC therapeutic and both proteins, and we assess the downstream pharmacodynamic effects.